Elizabeth L Jewell1, Juan Juan Huang2, Nadeem R Abu-Rustum3, Ginger J Gardner3, Carol L Brown3, Yukio Sonoda3, Richard R Barakat3, Douglas A Levine3, Mario M Leitao3. 1. Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Obstetrics and Gynecology, Weill Cornell Medical Center, New York, NY, USA. Electronic address: jewelle@mskcc.org. 2. College of the Holy Cross, Worcester, MA, USA. 3. Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Obstetrics and Gynecology, Weill Cornell Medical Center, New York, NY, USA.
Abstract
OBJECTIVES: Our primary objective was to assess the detection rate of sentinel lymph nodes (SLNs) using indocyanine green (ICG) and near-infrared (NIR) fluorescence imaging for uterine and cervical malignancies. METHODS: NIR fluorescence imaging for the robotic platform was obtained at our institution in 12/2011. We identified all cases planned for SLN mapping using fluorescence imaging from 12/2011-4/2013. Intracervical ICG was the fluorophobe in all cases. Four cc (1.25mg/mL) of ICG was injected into the cervix alone divided into the 3- and 9-o'clock positions, with 1 cc deep into the stroma and 1 cc submucosally before initiating laparoscopic entry. Blue dye was concurrently injected in some cases. RESULTS: Two hundred twenty-seven cases were performed. Median age was 60 years (range, 28-90 years). Median BMI was 30.2 kg/m(2) (range, 18-60 kg/m(2)). The median SLN count was 3 (range, 1-23). An SLN was identified in 216 cases (95%), with bilateral pelvic mapping in 179 (79%). An aortic SLN was identified in 21 (10%) of the 216 mapped cases. When ICG alone was used to map cases, 188/197 patients mapped, for a 95% detection rate compared to 93% (28/30) in cases in which both dyes were used (P=NS). Bilateral mapping was seen in 156/197 (79%) ICG-only cases and 23/30 (77%) ICG and blue dye cases (P=NS). CONCLUSIONS: NIR fluorescence imaging with intracervical ICG injection using the robotic platform has a high bilateral SLN detection rate and appears favorable to using blue dye alone and/or other modalities. Combined use of ICG and blue dye appears unnecessary.
OBJECTIVES: Our primary objective was to assess the detection rate of sentinel lymph nodes (SLNs) using indocyanine green (ICG) and near-infrared (NIR) fluorescence imaging for uterine and cervical malignancies. METHODS: NIR fluorescence imaging for the robotic platform was obtained at our institution in 12/2011. We identified all cases planned for SLN mapping using fluorescence imaging from 12/2011-4/2013. Intracervical ICG was the fluorophobe in all cases. Four cc (1.25mg/mL) of ICG was injected into the cervix alone divided into the 3- and 9-o'clock positions, with 1 cc deep into the stroma and 1 cc submucosally before initiating laparoscopic entry. Blue dye was concurrently injected in some cases. RESULTS: Two hundred twenty-seven cases were performed. Median age was 60 years (range, 28-90 years). Median BMI was 30.2 kg/m(2) (range, 18-60 kg/m(2)). The median SLN count was 3 (range, 1-23). An SLN was identified in 216 cases (95%), with bilateral pelvic mapping in 179 (79%). An aortic SLN was identified in 21 (10%) of the 216 mapped cases. When ICG alone was used to map cases, 188/197 patients mapped, for a 95% detection rate compared to 93% (28/30) in cases in which both dyes were used (P=NS). Bilateral mapping was seen in 156/197 (79%) ICG-only cases and 23/30 (77%) ICG and blue dye cases (P=NS). CONCLUSIONS: NIR fluorescence imaging with intracervical ICG injection using the robotic platform has a high bilateral SLN detection rate and appears favorable to using blue dye alone and/or other modalities. Combined use of ICG and blue dye appears unnecessary.
Authors: Beatrice Cormier; John P Diaz; Karin Shih; Rachael M Sampson; Yukio Sonoda; Kay J Park; Khaled Alektiar; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2011-05-13 Impact factor: 5.482
Authors: Robert W Holloway; Ricardo A Molero Bravo; Joseph A Rakowski; Jeffrey A James; Corinne N Jeppson; Susan B Ingersoll; Sarfraz Ahmad Journal: Gynecol Oncol Date: 2012-04-13 Impact factor: 5.482
Authors: D Cibula; N R Abu-Rustum; L Dusek; M Zikán; A Zaal; L Sevcik; G G Kenter; D Querleu; R Jach; A S Bats; G Dyduch; P Graf; J Klat; J Lacheta; C J L M Meijer; E Mery; R Verheijen; R P Zweemer Journal: Gynecol Oncol Date: 2011-11-25 Impact factor: 5.482
Authors: John P Diaz; Mary L Gemignani; Neeta Pandit-Taskar; Kay J Park; Melissa P Murray; Dennis S Chi; Yukio Sonoda; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2011-01-08 Impact factor: 5.482
Authors: Fady Khoury-Collado; Gretchen E Glaser; Oliver Zivanovic; Yukio Sonoda; Douglas A Levine; Dennis S Chi; Mary L Gemignani; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2009-09-19 Impact factor: 5.482
Authors: Jonathan T Elliott; Alisha V Dsouza; Scott C Davis; Jonathan D Olson; Keith D Paulsen; David W Roberts; Brian W Pogue Journal: Biomed Opt Express Date: 2015-09-03 Impact factor: 3.732
Authors: Rudy S Suidan; Charlotte C Sun; Scott B Cantor; Andrea Mariani; Pamela T Soliman; Shannon N Westin; Karen H Lu; Sharon H Giordano; Larissa A Meyer Journal: Obstet Gynecol Date: 2018-07 Impact factor: 7.661
Authors: Ane Gerda Zahl Eriksson; Margaret Montovano; Anna Beavis; Robert A Soslow; Qin Zhou; Nadeem R Abu-Rustum; Ginger J Gardner; Oliver Zivanovic; Richard R Barakat; Carol L Brown; Douglas A Levine; Yukio Sonoda; Mario M Leitao; Elizabeth L Jewell Journal: Ann Surg Oncol Date: 2016-02-23 Impact factor: 5.344
Authors: Robert W Holloway; Nadeem R Abu-Rustum; Floor J Backes; John F Boggess; Walter H Gotlieb; W Jeffrey Lowery; Emma C Rossi; Edward J Tanner; Rebecca J Wolsky Journal: Gynecol Oncol Date: 2017-05-28 Impact factor: 5.482
Authors: Anna L Beavis; Sergio Salazar-Marioni; Abdulrahman K Sinno; Rebecca L Stone; Amanda N Fader; Antonio Santillan-Gomez; Edward J Tanner Journal: Gynecol Oncol Date: 2016-08-12 Impact factor: 5.482